Phase I data from a combination approach involving CD137/4-1BB and OX-40 agonists and ivuxolimab in NSCLC and melanoma (NCT02315066) demonstrated good tolerability and preliminary anti-tumor activity in specific patient groups [339]. This evidence concerns the gene TNFRSF9 and melanoma.